Updated:
BeyondSpring Inc.
BeyondSpring Inc. is a biopharmaceutical company, not a family office.
BeyondSpring Inc.
BeyondSpring Inc. is a biopharmaceutical company, not a family office. The firm's primary focus is on developing cancer treatments, including its lead asset, plinabulin, a novel small molecule compound. Publicly available information indicates the company is headquartered in New York City. The firm has not publicly disclosed financial details such as AUM or deployment figures. Its operations are focused on drug development rather than investment management. No team size, offices, or recent activity beyond public filings were available in the provided sources. The firm's structure as a public company differs from that of a family office, with no disclosed family wealth origin.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at BeyondSpring Inc.?
BeyondSpring Inc. is a publicly traded biopharmaceutical company, not a family office. Investment decisions are made by its board of directors and management team, led by CEO Dr. Lan Huang. The firm focuses on drug development rather than capital allocation.
How does BeyondSpring Inc. source proprietary deal flow?
BeyondSpring Inc. is a clinical-stage drug developer, not an investment firm. It does not source deal flow; it develops its own drug candidates, primarily plinabulin, for cancer treatment. Its strategy involves in-house research and clinical trials.
Is BeyondSpring Inc. structured as a single family office or does it operate more like a biopharmaceutical company?
BeyondSpring Inc. is structured as a publicly traded biopharmaceutical company (NASDAQ: BYSI), not a family office. It is regulated by the SEC and focuses on drug development and commercialization. It does not manage external capital like a family office.
Does BeyondSpring Inc. participate in fund commitments or only direct investments?
BeyondSpring Inc. does not make fund commitments or direct investments in the traditional sense. As a biopharmaceutical firm, it uses its capital to fund research and development. It may engage in partnerships or licensing agreements but does not operate as an investment vehicle.
What investment stages does BeyondSpring Inc. typically target?
BeyondSpring Inc. does not target investment stages. It is a clinical-stage biotechnology company focused on developing therapies through phases of clinical trials. Its capital is allocated to drug research, clinical trials, and regulatory activities.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: